Table 2 Association between Id-1, EGFR, VEGF, tumour grade and Dukes' stage.
From: Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
| Â | Grade | Dukes' Stage | |||
|---|---|---|---|---|---|
| Â | G1(n = 10) | G2 (n = 21) | G3 (n = 15) | A+B (n = 19) | C+D (n = 27) |
Id-1 | Â | Â | Â | Â | Â |
   Absent | 2 (20%) | 1 (4.8%) | 0 (0%) | 3 (15.8%) | 0 (0%) |
   Weak | 3 (30%) | 9 (42.8%) | 1 (6.7%) | 2 (10.6%) | 3 (11.1%) |
   Moderate | 5 (50%) | 8 (38.1%) | 5 (33.3%) | 6 (31.5%) | 10 (37%) |
   Strong | 0 (0%) | 3 (14.3%) | 9 (60%) | 8 (42.1%) | 14 (51.9%) |
   p-value | p = 0.005 (G1 versus G2) | p = 0.0012 (G2 versus G3) | p = 0.018 | ||
EGFR | Â | Â | Â | Â | Â |
   Absent | 3 (30%) | 2 (9.5%) | 0 (0%) | 5 (26.4%) | 0 (0%) |
   Weak | 3 (30%) | 8 (38.1%) | 2 (13.3%) | 3 (15.8%) | 5 (18.6%) |
   Moderate | 3 (30%) | 7 (33.3%) | 3 (20%) | 4 (21%) | 9 (33.3%) |
   Strong | 1 (10%) | 4 (19.1%) | 10 (66.7%) | 7 (36.8%) | 3 (48.1%) |
   p-value | p = 0.002 (G1 versus G2) | p = 0.001 (G2 versus G3) | p = 0.03 | ||
VEGF | Â | Â | Â | Â | Â |
   Absent | 3 (30%) | 1 (4.7%) | 0 (0%) | 4 (21%) | 0 (0%) |
   Weak | 2 (20%) | 7 (33.3%) | 1 (6.7%) | 3 (15.8%) | 5 (18.6%) |
   Moderate | 2 (20%) | 8 (38.1%) | 3 (20%) | 5 (26.4%) | 10 (37%) |
   Strong | 3 (30%) | 5 (23.9%) | 11 (73.3%) | 7 (36.8%) | 12 (44.4%) |
   p-value | p = 0.05 (G1 versus G2) | p = 0.04 (G2 versus G3) | p = 0.04 | ||